Related Experiment Video
Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The evolving field of stroke prevention in patients with atrial fibrillation
Michael D Ezekowitz1, Timothy H Aikens, Annamarie Brown
1Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA. ezekowitzm@mlhs.org
Abstract:
Vitamin K antagonists have been the standard in stroke prophylaxis in patients with atrial fibrillation for decades, but several limitations make it difficult for patients to tolerate chronic anticoagulation treatment. New drugs are under evaluation in clinical trials, including direct thrombin inhibitors and factor Xa inhibitors. Antiplatelet agents such as clopidogrel and aspirin are alternatives to warfarin for stroke prevention but have proven less efficacious in trials. The only drug to have completed a Phase III trial successfully thus far is dabigatran. The 150-mg twice-a-day dose was superior to warfarin in efficacy and similar for major bleeding, whereas the 110-mg twice-a-day dose was noninferior for efficacy and reduced major bleeding. Both doses reduced intracranial hemorrhages substantially compared with warfarin. Dabigatran-assigned patients had a higher incidence of discontinuation due to gastrointestinal symptoms. Clinically apparent myocardial infarction rates were slightly higher in the dabigatran groups than the warfarin group. Dabigatran is the first agent to show superiority over warfarin for stroke prevention in atrial fibrillation, raising the standard for newer agents.
Insights
Dabigatran offers superior stroke prevention for atrial fibrillation patients compared to warfarin. While effective, some patients experienced gastrointestinal issues, and myocardial infarction rates were slightly higher.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Vitamin K antagonists (VKAs) are standard for stroke prevention in atrial fibrillation (AF).
- Limitations in VKA tolerance necessitate exploring alternative anticoagulation therapies.
- Direct thrombin and factor Xa inhibitors are under investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of dabigatran compared to warfarin for stroke prevention in AF patients.
- To assess the impact of different dabigatran doses on stroke risk, bleeding events, and other adverse outcomes.
Main Methods:
- Phase III clinical trial comparing dabigatran (110 mg and 150 mg twice daily) with warfarin.
- Assessment of stroke incidence, major bleeding, intracranial hemorrhages, and myocardial infarction rates.
Main Results:
- The 150-mg dose of dabigatran was more effective than warfarin for stroke prevention and similar in major bleeding risk.
- The 110-mg dose was non-inferior for efficacy and reduced major bleeding.
- Both dabigatran doses significantly reduced intracranial hemorrhages compared to warfarin.
- Higher rates of discontinuation due to gastrointestinal symptoms were observed with dabigatran.
- Slightly increased rates of clinically apparent myocardial infarction were noted in dabigatran groups.
Conclusions:
- Dabigatran represents a significant advancement in stroke prevention for AF, demonstrating superiority over warfarin.
- Dabigatran offers a valuable alternative anticoagulation option, though gastrointestinal side effects and monitoring for myocardial infarction are important considerations.
Related Concept Videos
Atherosclerosis IV: Nursing Management
Dysrhythmias VI: Management of Dysrhythmias
Venous Thrombosis III: Interprofessional Care
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Coronary Artery Disease IV: Preventive Measures
Hemorrhagic Stroke ll: Pathophysiology

